ID: MRFR/HC/6238-CR | 99 Pages | Author: Rahul Gotadki | April 2019
The Duloxetine API market is projected to grow at 3.20% CAGR to reach USD 4.59 billion during the forecast period
The Duloxetine API Market is projected to reach USD 4.59 billion by 2030 at CAGR 3.20% during the forecast period 2022-2030. The Duloxetine API is an inhibitor that is prescribed for neuropathic pain and depression and other mental disorders. Medical practitioners prescribe these drugs to patients with serious mental illnesses, to treat anxiety and serious depression. The drug is effective in impacting the neurotransmitters that are released by the brain nerves and thereby treating the mental illness of the patients. The growing number of anxiety and health care expenditures are propelling the overall growth of the Duloxetine API industry. The increasing geriatric population and the development of small molecular drugs are positively impacting the growth of the Duloxetine API industry.
The growing research and development activities in the medical sector and the increasing awareness related to the disease and the efficacy of the medications are propelling the overall growth of the Duloxetine API industry. The drugs are effective for treating urinary incontinence and a growing number of clinical trials related to API molecules are propelling the overall growth of the Duloxetine API market growth in recent times.
COVID 19 has created a serious impact on trading and industrial activities. The manufacturing sectors were also utilizing strategies to bring back the sales channels and productivity. They were also working towards product innovation and other categories of sales and marketing. Such factors have impacted the growth of the Duloxetine (API) industry positively. However, the growth of the Duloxetine (API) industry is expected to stabilize after the reduction in the COVID cases and normalcy.
The increasing number of neuro patients, anxiety disorders, and other health conditions were considered the key drivers of the Duloxetine (API) industry.
The growing geriatric population and increasing investment towards the growth of the medical industry coupled with the rising awareness about the types of depression and other mental conditions are considered the major drivers of Duloxetine API market growth.
The research and development activities related to the Duloxetine (API) industry are increasing at a rapid pace and the commercialization of the drug and research were carried out based o the regulations, country demographics, import and export tariffs, disease epidemiology, and other factors are expected to propel the overall growth of Duloxetine API market growth during the forecast period.
A report from World Health Organization in the year 2015 stated that there were about 3.6% of anxiety disorders globally and it is expected to grow due to the unhealthy lifestyle and living environments. Aggressive living culture and standards have increased the number of anxiety cases and thereby expected to increase the overall growth of the Duloxetine API market growth during the forecast period. Moreover, the advent of generic drugs in the pharmaceutical industry and the outsourcing trends in the pharmaceutical industry are expected to increase the overall growth of the Duloxetine (API) industry during the forecast period.
The side effects such as suicidal thoughts, drowsiness, dizziness, negative effect on thinking or coordination, and other factors are considered the major restraints of the Duloxetine (API) industry.
The economical condition of the developing countries, changing economic condition of the developing countries which make them unable to support the R and D activities related to the industry are considered the major restraints of the Duloxetine (API) industry.
The issues related to the FDA approval for these API plants and the operational issues related to the API plants are considered the key challenges for the overall growth of the Duloxetine (API) industry.
The storage and disposal of the contents and the medications are critical; they should be away from excess heat and sunlight. The alteration of the contents when not stored or transported properly is considered a challenge for the overall growth of the Duloxetine (API) industry.
The growth of the Duloxetine API industry is influenced by the growing number of anxiety and depression cases across the globe. These conditions were considered orphan diseases some decades ago, however, the rising prevalence of these conditions is propelling the overall growth of the Duloxetine (API) industry.
Moreover, the higher efficacy of these drugs, primarily as they reduce the nerve pain and relieve conditions such as arthritis and chronic back pain, the demand for this Duloxetine (API) drugs is rapidly increasing across the globe. The key benefits of consuming these drugs have effectively improved mood, sleep, and stress levels. They have also proved effective in improving appetite, energy level, and nervousness. Therefore the medical practitioners are prescribing these to the patients who are suffering more than a controllable state.
The Duloxetine API market growth is influenced by the higher sustainability and due to the careful considerations of product synthesis during the production process. The manufacturers are focusing on waste reduction and other factors during the manufacturing process. Such factors have propelled the vendors from developed countries to adopt these drugs. Similarly, other favorable factors such as the utilization of the biocatalysis enzymes that are obtained from the organic solvents and renewable sources and the elimination of the hazardous chemicals are considered the major drivers of the Duloxetine (API) industry.
The manufacturing processes are designed to protect the environment stability and the ecosystem, increased recyclability and reusability of the products are considered the beneficiary factors that are propelling the Duloxetine (API) industry in recent times. Moreover, the intermediate manufacturers are focused to yield a purer product and keen concentration is provided to enhance the product lifecycle.
Based on the type of drug:
Based on indication:
Based on strength:
Based on drug class:
Based on application:
Currently, North America is holding the maximum market share in the duloxetine API industry, and held a higher market share in the year 2019 and is expected to dominate during the forecast period. The growing health care infrastructure and the developing economy are some of the factors that support and improve the duloxetine API industry across North America. Likewise, the increasing number of diabetes cases, chronic musculoskeletal pain, and other painful complaints are propelling the overall growth of the duloxetine API industry across the region. On the other hand, the increasing number of mental disorders and neurological diseases with higher work-life imbalance across the Asia-pacific region is propelling it to become the second-largest market share in the duloxetine API industry.
In the year 2021, one of the leading market players, Teva pharmaceutical received FDA approval from US legislation for a drug that effectively treats schizophrenia and recently the issues related to the legalities have slowed down.
In the year 2019, one of the leading market players, Novartis joined hands with Cellforcure-a France which is based in France this acquisition has enabled the companies to expand their portfolio and their initiatives have boosted the established players across the region.
This report has covered:
Duloxetine API market is projected to grow at a 3.20% CAGR between 2022-2030.
The Americas is expected to dominate the duloxetine API market.
Duloxetine API market is predicted to touch USD 4.59 billion by 2030.
The chronic musculoskeletal pain segment will dominate the duloxetine API market.
Different strategies adopted by industry players in the duloxetine API market include expansion, innovation, acquisition, and product development.
Key Questions Answered
Why Choose Market Research Future?